KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenet Healthcare (THC) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Tenet Healthcare (THC) over the last 17 years, with Q4 2025 value amounting to $48.0 million.

  • Tenet Healthcare's Change in Receivables rose 17741.94% to $48.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$20.0 million, marking a year-over-year increase of 9183.67%. This contributed to the annual value of -$20.0 million for FY2025, which is 9183.67% up from last year.
  • According to the latest figures from Q4 2025, Tenet Healthcare's Change in Receivables is $48.0 million, which was up 17741.94% from -$28.0 million recorded in Q3 2025.
  • Tenet Healthcare's Change in Receivables' 5-year high stood at $263.0 million during Q1 2024, with a 5-year trough of -$340.0 million in Q2 2024.
  • Moreover, its 5-year median value for Change in Receivables was $11.5 million (2021), whereas its average is $5.0 million.
  • As far as peak fluctuations go, Tenet Healthcare's Change in Receivables surged by 212000.0% in 2022, and later tumbled by 131428.57% in 2024.
  • Over the past 5 years, Tenet Healthcare's Change in Receivables (Quarter) stood at -$5.0 million in 2021, then surged by 2120.0% to $101.0 million in 2022, then plummeted by 40.59% to $60.0 million in 2023, then tumbled by 203.33% to -$62.0 million in 2024, then skyrocketed by 177.42% to $48.0 million in 2025.
  • Its Change in Receivables stands at $48.0 million for Q4 2025, versus -$28.0 million for Q3 2025 and -$109.0 million for Q2 2025.